Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$38.65 USD
+0.51 (1.34%)
Updated May 30, 2024 03:59 PM ET
After-Market: $38.90 +0.25 (0.65%) 7:30 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
Ultragenyx Pharmaceutical Inc. [RARE]
Reports for Purchase
Showing records 21 - 40 ( 328 total )
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
FY23 Preannouncement, FY24 Guidance Targets Arrive As Anticipated
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
GTX-102 Phase 1/2 Angelman Syndrome Study Completes Enrollment; Data in 1H24 to Inform Phase 3 Design; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
With Major Fireworks Shot Off, 3Q23 Update Largely As Anticipated
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Commercial Preview: Some Fireworks Ahead, But Prereleases Steal Thunder
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Upcoming Analyst Event Offers Closer Pipeline Look; In-Line Update For 2Q23
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
UX701 Pivotal Cyprus2+ Trial For Wilson Disease Advances Into Higher Dose; Initial Data Expected in 1H24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Commercial Biotech Preview: Could 2Q23 Reporting Help Restart a Rally?
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department